Compositions and methods for the treatment of cardiac surgery-associated acute kidney injury with annexin A1 peptide
US-9173918-B2 · Nov 3, 2015 · US
Methods and compositions for activation of sirtuins with Annexin A1 peptides
US10172915B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10172915-B2 |
| Application number | US-201414519000-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 20, 2014 |
| Priority date | Oct 20, 2013 |
| Publication date | Jan 8, 2019 |
| Grant date | Jan 8, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a method of treating, ameliorating or inhibiting sirtuin-associated disorders and/or conditions in a subject in need thereof, by administering to the subject an effective amount of an ANXA1 peptide.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of increasing the amount and/or the activity of one or more than one sirtuin in a subject in need thereof, comprising administering to the subject an effective amount of ANXA1 short peptide (ANXA1sp), wherein the subject has type 2 diabetes, a metabolic disorder, obesity, a fat-related metabolic disorder, a neurodegenerative disorder, a disorder resulting in cognitive decline, a spinal cord injury, a blood coagulation disorder, an ocular disorder, a respiratory disorder, a viral infection, a fungal infection, chronic hepatitis infection, an autoimmune disorder, flushing, a mitochondrial disease or disorder, a chemotherapy-induced neuropathy, a skin disorder, affliction or condition, a disorder associated with stress, stroke, arthritis, hypertension, Alzheimer's disease, liver disease, an inflammatory disorder, trauma and/or chronic pain associated with brain and/or spinal cord disease, disorder, damage or injury, and any combination thereof, and further comprising the step of administering one or more compounds selected from the group consisting of resveratrol, piceatannol, nicotinic acid, and any combination thereof, prior to, concurrent with and/or after administration of the ANXA1 short peptide. 2. The method of claim 1 , wherein the one or more than one sirtuin is selected from the group consisting of Sirtuin 1 (SIRT1), Sirtuin 2 (SIRT2), Sirtuin 3 (SIRT3), Sirtuin 4 (SIRT4), Sirtuin 5 (SIRT5), Sirtuin 6 (SIRT6) Sirtuin 7 (SIRT7), and any combination thereof.
Assignees
Inventors
Classifications
- A61K38/1709Primary
from mammals · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10172915B2 cover?
- The present invention provides a method of treating, ameliorating or inhibiting sirtuin-associated disorders and/or conditions in a subject in need thereof, by administering to the subject an effective amount of an ANXA1 peptide.
- Who is the assignee on this patent?
- Univ Duke
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).